Biologics Manufacturing and CDMO Partnerships Europe · 21h ago

Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany

Nanoform partners with German CDMO to GMP-manufacture ultra-high-concentration biologics via nanoforming, targeting clinical supply readiness in H2 2027.

RD

Research Desk

· 2 min read

Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany

A global CDMO headquartered in Europe will manufacture Nanoform's ultra-high-concentration biologics technology under GMP, following an agreement announced by the Helsinki-based company.

Dedicated Production Line Slated for Second-Half 2027 Readiness

Under the deal, a dedicated production line for the technology will be established within the CDMO's existing aseptic manufacturing facility in Germany, which already produces injectable biologics under Good Manufacturing Practice standards, including aseptic processing and fill-and-finish.

The two parties are targeting GMP readiness in the second half of 2027. That timeline is meant to underpin a planned first customer clinical trial of a subcutaneous ultra-high concentration suspension biologic product enabled by nanoforming.

Clinical Supply Framed as the Core Value for Customers

The collaboration is presented as an accelerated route for Nanoform's customers, running from formulation and preclinical work at Nanoform to GMP manufacture and supply of clinical trial material and later commercial manufacturing.

The company says that pairing its biologics technology and development capabilities with the CDMO's established aseptic infrastructure, quality systems, and manufacturing expertise speeds the transition into clinical development.

Chief Commercial Officer Christian Jones stressed the role of clinical supply, saying that enabling it is fundamental for Nanoform's customers and partners.

In his view, the partnership offers an accelerated pathway to GMP clinical supply with a CDMO that is a global leader in aseptic manufacturing and has a strong network to support the joint customers.

Chief Executive Officer Edward Hæggström welcomed the agreement, saying the company is pleased to have found an excellent partner to accelerate its customers' entry to clinics with subcutaneous ultra-high concentration suspension products enabled by nanoforming.

He noted that implementation work at the partner's site will take place in the coming months and that both Nanoform and its customers are impressed by the expertise and speed with which the cooperation has begun.

Nanoforming Technology Behind the Deal

The technology covered by the agreement is Nanoform's nanoforming platform. The company combines nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable what it calls superior medicines for patients.

Its stated aim is to reduce clinical attrition and enhance drug molecules' performance through nanoforming technologies and formulation services spanning preclinical to commercial scale.

According to Nanoform, its technologies are intended to improve bioavailability and drug delivery profiles, drive differentiation and patient adherence, and extend the lifecycle potential of products.

The company believes subcutaneous delivery will become the dominant standard for both new and marketed biologics, and its suspension formulations are designed to achieve high drug concentrations with particle properties it describes as critical for suspension performance.

Disclosure and Listing Details

Nanoform's shares trade on the Premier-segment of Nasdaq First North Growth Market in Helsinki under the ticker NANOFH and in Stockholm under NANOFS, with DNB Carnegie Investment Bank AB serving as certified adviser.

Nanoform, which describes itself as a medicine performance-enhancing company, stated that the agreement has no immediate material financial effect. Neither the partner's identity nor the financial terms were disclosed.

Tracked in the database

Biologics Manufacturing and CDMO Partnerships · Europe

Category

Biologics Manufacturing and CDMO Partnerships

Region

Europe

Industry

Chemical

Published

18 November 2026

Length

2 min read

Tagged

Biologics ManufacturingContract NanoformDevelopment and ManufacturingGMP ManufacturingAseptic ManufacturingHigh-Concentration BiologicsInjectable BiologicsSubcutaneous Drug DeliveryPharmaceutical Manufacturing

Live from the tracker

The projects behind these stories

Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.

LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning LLY - Lebanon Medicine Foundry · Indiana, United States · Not disclosed · On-going / Under Construction LLY - Project Savannah Biomanufacturing Facility · Texas, United States · Not disclosed · Planning LLY - Huntsville Medicines Manufacturing Plant · Alabama, United States · Not disclosed · Planning NOVO-B - Clayton Aseptic and Finished Product Manufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Pleasant Prairie Pharmaceutical Manufacturing Facility Expansion · Wisconsin, United States · Not disclosed · Planning EDCL - Gopalganj Vaccine Manufacturing Plant · Dhaka Division, Bangladesh · Not disclosed · Planning FF - Holly Springs Cell Culture Biomanufacturing Plant · North Carolina, United States · Not disclosed · On-going / Under Construction LLY - Leiden Bio Science Park Pharmaceutical Manufacturing Plant · Netherlands · Not disclosed · Planning LLY - Alzey Pharmaceuticals Production Plant · Rhineland-Palatinate, Germany · Not disclosed · On-going / Under Construction BAYN - New Albany Pharmaceutical Manufacturing Plant · Ohio, United States · Not disclosed · Planning